Idiopathic Pulmonary Fibrosis: Competitive Landscape to 2026

NEW YORK, April 25, 2019 /PRNewswire/ -- Download the full report: https://www.reportbuyer.com/product/5771121/?utm_source=PRN

Idiopathic pulmonary fibrosis (IPF) is a progressive disease that results in the scarring of lung tissue and changes the lung's ability to function normally.The most common signs and symptoms of idiopathic pulmonary fibrosis are dyspnea and a persistent nonproductive cough.

Many affected individuals also experience a loss of appetite and gradual weight loss.IPF primarily occurs in older adults.

However, the causes are unknown.

The report "Idiopathic Pulmonary Fibrosis: Competitive Landscape to 2026", uses in-house analyst expertise to provide a competitive assessment of the disease marketplace.

This report provides -
- The IPF pipeline consists of 132 drugs spanning all stages of development with approximately two-third of the drugs in the preclinical stage. The strength of the IPF pipeline is strong with 14 drugs, all with novel MOAs, in late-stage clinical development
- Close to 43% of IPF clinical trials have been conducted in North America between 2010-2017. 66 clinical trials were recorded in North America between 2010-2017Overall, IPF clinical trials have had relatively high enrollment efficiencies in all phases except for Phase III, which had close to 84% efficiency
- Phase II clinical trials had the highest enrollment efficiency (105%), which could be due to patients being more willing to participate due to increased confidence in the safety and efficacy of a late-stage drug

Companies mentioned: Roche, Boehringer Ingelheim, Zambon, Galapagos NV, Prometic Life Sciences Inc, Novartis, Biogen, Promedior, FibroGen

Scope
- Pipeline Assessment-regional breakdown, promising late-stage products, early-stage pipeline by molecule type
- Clinical Trials Assessment-trial breakdown by phase, leading industry and non-industry sponsors, enrollment analytics
- Commercial Assessment-leading marketed products, current and future players
- Competitive Landscape Analysis-key market events (2016-2026).

Reasons to buy
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global IPF market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global IPF market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.

Download the full report: https://www.reportbuyer.com/product/5771121/?utm_source=PRN

About Reportbuyer
Reportbuyer is a leading industry intelligence solution that provides all market research reports from top publishers

For more information:
Sarah Smith
Research Advisor at Reportbuyer.com
Email: [email protected]
Tel: +1 (718) 213 4904
Website: www.reportbuyer.com

SOURCE ReportBuyer

Related Links

http://www.reportbuyer.com

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED